{
    "clinical_study": {
        "@rank": "126011", 
        "arm_group": {
            "arm_group_label": "PK", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, multicenter, 3-period, fixed-sequence study will evaluate the effect of\n      multiple oral doses of vemurafenib on the pharmacokinetics of a single oral dose of\n      tizanidine in patients with BRAFV600  mutation-positive metastatic malignancies. Patients\n      will receive a single oral dose of tizanidine on Day 1, vemurafenib orally twice daily on\n      Days 2-21, and tizanidine and vemurafenib on Day 22. Eligible patients will have the option\n      to continue treatment with vemurafenib as part of an extension study (NCT01739764)."
        }, 
        "brief_title": "A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Melanoma, Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Melanoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, 18 to 70 years of age, inclusive\n\n          -  Patients with either unresectable Stage IIIc or IV metastatic melanoma positive for\n             the BRAFV600 mutation or other malignant tumor type which harbors a V600 activating\n             mutation of BRAF, as determined by Cobas 4800 BRAFV600 Mutation Test or a DNA\n             sequencing method\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n\n          -  Life expectancy >/= 12 weeks\n\n          -  Patient has not consumed tobacco or nicotine-containing products for 6 weeks prior to\n             first dose of study drug, and must agree to refrain from such products while on study\n\n          -  Adequate hematologic, renal and liver function\n\n        Exclusion Criteria:\n\n          -  Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Day 1,\n             period A\n\n          -  History of or current clinically significant cardiac or pulmonary dysfunction,\n             including current uncontrolled Grade >/= 2 hypertension or unstable angina\n\n          -  Current dyspnea at rest due to complications of advanced malignancy or any\n             requirement for supplemental oxygen\n\n          -  Active central nervous system lesions (i.e. patients with radiographically unstable,\n             symptomatic lesions)\n\n          -  Patients with CYP2A2 gene mutation (-3113G->A)\n\n          -  Allergy or hypersensitivity to vemurafenib or tizanidine formulations\n\n          -  Current severe uncontrolled systemic disease\n\n          -  Inability or unwillingness to swallow pills\n\n          -  History of malabsorption or other condition that would interfere with enteral\n             absorption of study treatment\n\n          -  History of clinically significant liver disease including cirrhosis), current alcohol\n             abuse, or HIV infection requiring antiretroviral treatment, AIDS-related illness, or\n             active hepatitis B or C\n\n          -  Active autoimmune disease\n\n          -  Pregnant or breastfeeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844674", 
            "org_study_id": "GO28396", 
            "secondary_id": "2012-003705-94"
        }, 
        "intervention": [
            {
                "arm_group_label": "PK", 
                "description": "multiple oral doses", 
                "intervention_name": "vemurafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PK", 
                "description": "single oral doses", 
                "intervention_name": "tizanidine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tizanidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Pleasant Hill", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94523"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Derqui-Pilar", 
                        "country": "Argentina", 
                        "zip": "B1629ODT"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosario", 
                        "country": "Argentina", 
                        "zip": "S2000KZE"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil", 
                        "state": "RJ", 
                        "zip": "20560-120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ijui", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "98700-000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Passo Fundo", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "99010-260"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90610-000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenfield Park", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J4V 2H1"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nicosia", 
                        "country": "Cyprus", 
                        "zip": "2006"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-749"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Brazil", 
                "Canada", 
                "Cyprus", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE I, OPEN-LABEL, MULTICENTER, 3- PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF SINGLE DOSE OF TIZANIDINE (A CYP1A2 SUBSTRATE) IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO28396 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 12 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 12 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Time to maximum plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 12 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Terminal half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 12 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Apparent clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 12 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844674"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: Incidence, nature and severity of adverse events and serious adverse events, graded according to the NCI CTAE (Version 4.0)", 
            "safety_issue": "No", 
            "time_frame": "approximately 1.5 years"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}